Project Description

Teva Pharmaceutical Industries Ltd. (TEVA)

Teva Pharmaceutical Industries Ltd. is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. We deliver high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. We have an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. We strive to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, we employ 45,000 professionals, committed to improving the lives of millions of patients. Learn more at www.tevapharm.com.

Teva shares leadership of the project with the Coordinator RCSI, as well as contributing to the in vitro research program:

  • conducting quantitative studies of mitochondrial bioenergetics in vitro, and
  • examining the effects of αSyn fibrils on neuronal excitability in vitro.
Teva Pharmaceutical Industries Ltd logo
Ian Reynolds
Ian Reynolds
Project Leader
Sara Shnider
Sara Shnider
Project Manager, Innovation, IP Management and Commercialisation Co-Chair
Ianai Fishbein
Ianai Fishbein
Head of in vitro team, non-clinical development
Inbal Ben Eliezer
Inbal Ben Eliezer
In vitro scientist, non-clinical development
Marko Kostic
Marko Kostic
In vitro scientist, non-clinical development